Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIADA Trial: Nivolumab with neoadjuvant chemo-endocrine therapy in premenopausal luminal B breast cancer
2016-004665-10Phase 2Completed
- Sponsor
- Department of Surgical Oncological and Gastroenterological Sciences
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in breast cancer, sponsored by Department of Surgical Oncological and Gastroenterological Sciences. Primary endpoint: Pathological complete response rate. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-004665-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004665-10.